Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.51 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.50 |
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452347 | 0.98 | IDO1 (0.50) | IDO1GPR84BRD4PDPK1 | |
| SCHEMBL449978 | 0.95 | IDO1 (0.53) | IDO1GPR84BRD4PDPK1 | |
| SCHEMBL448693 | 0.89 | IDO1 (0.56) | IDO1GPR84BRD4PDPK1 | |
| SCHEMBL9626216 | 0.84 | IDO1 (0.51) | IDO1GPR84PDPK1 | |
| SCHEMBL448659 | 0.82 | IDO1 (0.59) | IDO1GPR84BRD4PDPK1 | |
| SCHEMBL19359157 | 0.79 | IDO1 (0.56) | IDO1GPR84PDPK1 | |
| SCHEMBL7410008 | 0.79 | IDO1 (0.61) | IDO1GPR84PDPK1 | |
| SCHEMBL19359221 | 0.79 | IDO1 (0.56) | IDO1GPR84PDPK1 | |
| SCHEMBL30728437 | 0.79 | GPR84 (0.57) | IDO1GPR84PDPK1 | |
| SCHEMBL7846356 | 0.79 | HTR2C (0.53) | IDO1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | IDO1 646/4885GPR84 1196/4885BRD4 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.